retatrutide gip glp-1 glucagon receptor agonist peptide for weight loss and fat burning Targeting GLP-1, GIP & GCG

In addition to GLP-1 medications, Fridays also offers longevity and hormone therapies, including NAD+ therapy for about $259/month and testosterone replacement therapy (TRT) in multiple formats starting around $189/month, with bundle discounts available that can reduce the overall monthly cost when treatments are combined

Seino Y, Rasmussen MF, Zdravkovic M, et al

tirzepatide is a dual agonist (GIP/GLP-1) Peak weight loss : Retatrutide showed 28.7% at 68 weeks (Phase 3 TRIUMPH-4) and 24.2% at 48 weeks (Phase 2) vs tirzepatide 20.9% (Phase 3) Liver fat : Retatrutide's glucagon agonism provides pronounced hepatic fat reduction (up to 82%) Regulatory status : Tirzepatide is FDA-approved

Many healthcare professionals and patients find it helpful to start GLP-1 therapy at the beginning of a weekend or during a period of reduced work or social commitments

And not every patient should avoid medication

Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, et al